SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400,233 | -9.6% | 14,517 | -1.4% | 0.00% | 0.0% |
| Q2 2023 | $442,633 | -18.0% | 14,725 | -1.2% | 0.00% | -25.0% |
| Q1 2023 | $539,826 | -2.2% | 14,900 | -3.7% | 0.00% | 0.0% |
| Q4 2022 | $551,992 | -17.2% | 15,475 | -21.5% | 0.00% | -33.3% |
| Q3 2022 | $667,000 | +17.0% | 19,710 | 0.0% | 0.01% | +20.0% |
| Q2 2022 | $570,000 | -10.5% | 19,710 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $637,000 | +6.5% | 19,710 | -4.0% | 0.00% | 0.0% |
| Q4 2021 | $598,000 | +28.3% | 20,525 | +17.3% | 0.00% | +33.3% |
| Q3 2021 | $466,000 | -19.5% | 17,495 | -7.0% | 0.00% | -25.0% |
| Q2 2021 | $579,000 | +17.2% | 18,815 | -0.3% | 0.00% | 0.0% |
| Q1 2021 | $494,000 | +47.0% | 18,875 | +41.3% | 0.00% | +33.3% |
| Q4 2020 | $336,000 | +19.1% | 13,355 | -1.3% | 0.00% | 0.0% |
| Q3 2020 | $282,000 | +25.3% | 13,535 | +42.6% | 0.00% | +50.0% |
| Q2 2020 | $225,000 | – | 9,490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |